International Psoriasis Council

Advancing Knowledge. Improving Care.

IPC Welcomes Oruka Therapeutics as a 2025 Bronze Level Corporate Member

We’re excited to announce that Oruka Therapeutics has joined the International Psoriasis Council as a 2025 Bronze Level Corporate Member. Oruka is a pioneering biopharmaceutical company advancing potentially best-in-class monoclonal antibody therapies for plaque psoriasis, psoriatic arthritis, and related inflammatory skin conditions. Their seasoned team of biopharma professionals is dedicated to improving patient experiences through innovative biologic treatments.

“We’re delighted to welcome Oruka into the IPC community,” said IPC CEO Christy Langan. “Their focus on developing targeted antibody therapies will deepen our collective understanding of psoriasis biology and support our goal of improving care for people living with this disease.”

Please join us in extending a warm welcome to Oruka.

Learn more about Oruka Therapeutics.

[searchwp_search_form engine=blog_search target="/news" var=_blog_search]

Categories

Recent Posts

Six people stand side by side in business attire, smiling at the camera. Behind them, a banner reads IPC International Council 2025 Think Tank Puerto Rico, focused on Psoriasis in Latin America, with colorful designs and sunlight filtering through curtains.

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

VIEW
A large group attends a conference session, with several panelists seated at a table onstage. One attendee stands to ask a question. The IPC (International Psoriasis Council) logo and AAD 2026 appear in the corner.

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

VIEW
A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

VIEW

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »
Monday, April 27, 2026

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026